• Explore /
  • Poster
  • / Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.

Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.

Abstract Poster

Authors

null

Vikas Gupta

Princess Margaret Cancer Center, Toronto, ON, Canada

Vikas Gupta , Maria R. Baer , Stephen T. Oh , Carole Brennan Miller , Susie Jun , Peter Lee , Hua Dong , Andreas Reiter

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT02101268

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS7102)

DOI

10.1200/jco.2015.33.15_suppl.tps7102

Abstract #

TPS7102

Poster Bd #

87a

Abstract Disclosures

Similar Posters

First Author: Lucia Masarova

First Author: Elliott F. Winton

First Author: Ruben A. Mesa

First Author: Aaron Thomas Gerds